OTCPK:VASO

Stock Analysis Report

Executive Summary

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally.

Snowflake

Fundamentals

Overvalued with worrying balance sheet.

Risks

  • Vaso has significant price volatility in the past 3 months.
  • Vaso is not covered by any analysts.

Similar Companies

Share Price & News

How has Vaso's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.1%

VASO

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-61.6%

VASO

9.9%

US Medical Equipment

0.7%

US Market

VASO underperformed the Medical Equipment industry which returned 9.9% over the past year.

VASO underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

VASOIndustryMarket
7 Day-5.1%1.1%-0.6%
30 Day-10.1%1.3%2.9%
90 Day-26.2%3.0%1.3%
1 Year-61.6%-61.6%10.8%9.9%2.9%0.7%
3 Year-87.0%-87.0%70.1%64.9%44.6%35.2%
5 Year-91.1%-91.1%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Vaso's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vaso undervalued based on future cash flows and its price relative to the stock market?

1.34x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Vaso to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Vaso to establish if it is available at substantial discount.


Price Based on Earnings

Vaso is loss making, we can't compare its value to the US Medical Equipment industry average.

Vaso is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Vaso, we can't assess if its growth is good value.


Price Based on Value of Assets

Vaso is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Vaso expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaso has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of VASO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Vaso's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Vaso performed over the past 5 years?

-51.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Vaso does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Vaso's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Vaso's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Vaso has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Vaso has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Vaso improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Vaso's financial position?


Financial Position Analysis

Vaso's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Vaso's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Vaso's level of debt (528.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.3% vs 528.8% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Vaso has less than a year of cash runway based on current free cash flow.

Vaso has less than a year of cash runway if free cash flow continues to grow at historical rates of 110.9% each year.


Next Steps

Dividend

What is Vaso's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Vaso's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Vaso's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Vaso has not reported any payouts.

Unable to verify if Vaso's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Vaso has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Vaso's salary, the management and board of directors tenure and is there insider trading?

8.0yrs

Average management tenure


CEO

Jun Ma (56yo)

10.9yrs

Tenure

US$407,476

Compensation

Dr. Jun Ma, Ph. D. has been the President and Chief Executive Officer of Vasomedical Inc. since October 16, 2008. Dr. Ma serves as an Executive Vice President at Chengdu Top Sci-Tech Co. Ltd. He served as  ...


CEO Compensation Analysis

Jun's remuneration is about average for companies of similar size in United States of America.

Jun's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

8.0yrs

Average Tenure

65yo

Average Age

The average tenure for the Vaso management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

8.8yrs

Average Tenure

64.5yo

Average Age

The tenure for the Vaso board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Michael Beecher (74yo)

    CFO & Secretary

    • Tenure: 8yrs
    • Compensation: US$225.29k
  • Peter Castle (51yo)

    COO & Director

    • Tenure: 9.1yrs
    • Compensation: US$374.47k
  • Jun Ma (56yo)

    President

    • Tenure: 10.9yrs
    • Compensation: US$407.48k
  • Derek Enlander (73yo)

    • Tenure: 8.6yrs
    • Compensation: US$33.00k
  • Jonathan Newton (58yo)

    VP of Finance & Treasurer

    • Tenure: 8yrs
    • Compensation: US$186.59k
  • Randy Hill (72yo)

    Consultant

    • Tenure: 0yrs
    • Compensation: US$105.00k

Board Members

  • David Lieberman (74yo)

    Vice Chairman

    • Tenure: 8.6yrs
    • Compensation: US$54.53k
  • Peter Castle (51yo)

    COO & Director

    • Tenure: 9.1yrs
    • Compensation: US$374.47k
  • Edgar Rios (67yo)

    Director

    • Tenure: 8.6yrs
    • Compensation: US$50.56k
  • Jun Ma (56yo)

    President

    • Tenure: 10.9yrs
    • Compensation: US$407.48k
  • Behnam Movaseghi (66yo)

    Independent Director

    • Tenure: 12.2yrs
    • Compensation: US$50.56k
  • Joshua Markowitz (63yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$45.56k

Company Information

Vaso Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vaso Corporation
  • Ticker: VASO
  • Exchange: OTCPK
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.918m
  • Shares outstanding: 172.66m
  • Website: https://www.vasocorporation.com

Number of Employees


Location

  • Vaso Corporation
  • 137 Commercial Street
  • Unit 200
  • Plainview
  • New York
  • 11803
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VASOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 1988

Biography

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three seg ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:46
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.